BR112012020953A2 - produto, uso do mesmo, metodo para prevencao e/ou tratamento de fibrose corneana ou opacidade corneana e composicao farmaceutica oftalmica - Google Patents

produto, uso do mesmo, metodo para prevencao e/ou tratamento de fibrose corneana ou opacidade corneana e composicao farmaceutica oftalmica

Info

Publication number
BR112012020953A2
BR112012020953A2 BR112012020953A BR112012020953A BR112012020953A2 BR 112012020953 A2 BR112012020953 A2 BR 112012020953A2 BR 112012020953 A BR112012020953 A BR 112012020953A BR 112012020953 A BR112012020953 A BR 112012020953A BR 112012020953 A2 BR112012020953 A2 BR 112012020953A2
Authority
BR
Brazil
Prior art keywords
corneal
prevention
treatment
product
pharmaceutical composition
Prior art date
Application number
BR112012020953A
Other languages
English (en)
Portuguese (pt)
Inventor
Dotor De Las Herreria Javier
Jose Maldonado Lopez Miguel
Original Assignee
Digna Biotech Sl
Proyecto De Bimedicina Cima S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Digna Biotech Sl, Proyecto De Bimedicina Cima S L filed Critical Digna Biotech Sl
Publication of BR112012020953A2 publication Critical patent/BR112012020953A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012020953A 2010-02-22 2011-02-21 produto, uso do mesmo, metodo para prevencao e/ou tratamento de fibrose corneana ou opacidade corneana e composicao farmaceutica oftalmica BR112012020953A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/709,895 US8158589B2 (en) 2003-08-22 2010-02-22 Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
PCT/EP2011/052543 WO2011101478A1 (en) 2010-02-22 2011-02-21 USE OF TRANSFORMING GROWTH FACTOR - BETA 1 (TGF-β1) INHIBITOR PEPTIDES FOR THE TREATMENT OF CORNEAL FIBROSIS AND/OR HAZE

Publications (1)

Publication Number Publication Date
BR112012020953A2 true BR112012020953A2 (pt) 2017-02-07

Family

ID=43757920

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012020953A BR112012020953A2 (pt) 2010-02-22 2011-02-21 produto, uso do mesmo, metodo para prevencao e/ou tratamento de fibrose corneana ou opacidade corneana e composicao farmaceutica oftalmica

Country Status (10)

Country Link
US (2) US8158589B2 (cg-RX-API-DMAC7.html)
EP (1) EP2538962A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013520405A (cg-RX-API-DMAC7.html)
CN (1) CN102791283A (cg-RX-API-DMAC7.html)
AU (1) AU2011217181A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012020953A2 (cg-RX-API-DMAC7.html)
CA (1) CA2790625A1 (cg-RX-API-DMAC7.html)
MX (1) MX2012009748A (cg-RX-API-DMAC7.html)
RU (1) RU2012140704A (cg-RX-API-DMAC7.html)
WO (1) WO2011101478A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158103A1 (en) * 2011-11-23 2013-06-20 The Curators Of The University Of Missouri Method of Tissue-Selective Targeted Gene Transfer
ES2423382B1 (es) * 2012-02-16 2014-07-15 Consejo Superior De Investigaciones Científicas (Csic) Inhibidor de la produccion de endoglina soluble y su aplicacion en patologias donde la endoglina soluble tiene un efecto patogenico
WO2013148155A1 (en) * 2012-03-26 2013-10-03 Digna Biotech Usa, Llc Compositions and methods for the treatment of dry eye disease
WO2014028862A1 (en) 2012-08-17 2014-02-20 Cornell University Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
MX386503B (es) * 2013-07-30 2025-03-19 Kyoto Prefectural Public Univ Corp Medicamentos terapeuticos de matriz extracelular endotelial corneal.
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10813920B2 (en) 2013-11-14 2020-10-27 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
WO2015153732A2 (en) 2014-04-01 2015-10-08 Cornell University Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
WO2016057702A2 (en) 2014-10-07 2016-04-14 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
HRP20240306T1 (hr) * 2015-10-27 2024-05-10 Taipei Medical University Derivati indolina za liječenje i/ili prevenciju fibroznih bolesti
EP3381472A4 (en) 2015-12-24 2019-07-31 The Doshisha MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
US11576914B2 (en) 2017-07-26 2023-02-14 The Doshisha Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
GB201908012D0 (en) * 2019-06-05 2019-07-17 Io Biotech Aps TGF-Beta vaccine
RU2700941C1 (ru) * 2019-07-05 2019-09-24 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) Способ предупреждения развития помутнения роговицы при ее механических травмах
RU2701178C1 (ru) * 2019-07-10 2019-09-25 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр реабилитации и курортологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ РК" Минздрава России) Способ ускорения заживления роговицы при ее механических травмах
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
CN110862434B (zh) * 2019-10-28 2021-07-06 中山大学 一种可促进TGF-β1蛋白靶向降解的化合物及其制备方法与应用
JP2020073483A (ja) * 2019-10-30 2020-05-14 京都府公立大学法人 角膜内皮ecm治療薬
AU2021409832A1 (en) * 2020-12-23 2023-08-10 Korea Institute Of Science And Technology NOVEL PEPTIDE CAPABLE OF INHIBITING TGF-β SIGNALING AND USE THEREOF
CN115040535B (zh) * 2022-08-15 2022-12-16 华南理工大学 硫酸化透明质酸在制备预防角膜纤维化、角膜瘢痕滴眼液中的应用
WO2026027520A1 (en) 2024-07-30 2026-02-05 Disit Biotech, S.L. Method of preparing parenteral formulations and formulations prepared therefrom

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Hla結合性オリゴペプチド及びそれを含有する免疫調節剤
WO1998024466A1 (en) * 1996-12-05 1998-06-11 Alcon Laboratories, Inc. THE USE OF INHIBITORS OF TGF-β'S FUNCTIONS TO AMELIORATE OCULAR PATHOLOGY
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6399107B1 (en) 1998-12-22 2002-06-04 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
ATE434442T1 (de) 2000-10-13 2009-07-15 Univ Johns Hopkins Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser- sehkraftkorrektur-chirurgie
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
AU2005337776B2 (en) * 2005-10-24 2013-01-31 Proyecto De Biomedicina Cima, S.L. Use of TGF-Beta1 inhibitor peptides in the preparation of an immune response modulating agent
US7582609B2 (en) * 2006-03-01 2009-09-01 Digna Biotech, S.L. Method for the treatment of skin fibrosis and suitable compositions for such treatment

Also Published As

Publication number Publication date
MX2012009748A (es) 2012-12-05
US8158589B2 (en) 2012-04-17
WO2011101478A1 (en) 2011-08-25
AU2011217181A1 (en) 2012-09-06
JP2013520405A (ja) 2013-06-06
CN102791283A (zh) 2012-11-21
EP2538962A1 (en) 2013-01-02
US20100222280A1 (en) 2010-09-02
RU2012140704A (ru) 2014-03-27
US20120315256A1 (en) 2012-12-13
CA2790625A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
EP4414376A3 (en) Novel depsipeptide and uses thereof
WO2012168430A3 (en) Polypeptides
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
HK1232147A1 (zh) 用於治疗纤维化的赛尼克韦罗
BR112013015855A2 (pt) composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
WO2012004706A3 (en) Chemical compounds
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
BRPI0816255A2 (pt) Produto farmacêutico, uso do produto, método para a profilaxia ou o tratamento de doenças, e, composição farmaceuticamente aceitável
HK1244806A1 (zh) 作為過氧乙醯硝酸整聯蛋白拮抗劑的間氮雜環氨基苯甲酸衍生物
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
WO2016077656A3 (en) Methods and compositions for inhibition of bromodomain and extraterminal proteins
WO2015117841A3 (en) Meta-stable o/w emulsions
HK1259441A1 (zh) 包含btk抑制剂的制剂/组合物
NZ708821A (en) Lfa-1 inhibitor formulations
BR112013015877A2 (pt) composto, uso de um composto, métodos de prevenção. tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica.
WO2012161497A3 (ko) 보습능이 우수한 펩타이드 유도체 및 이의 용도
AU2015278731B2 (en) Fused triterpene compounds and uses thereof
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
BRPI0818813A2 (pt) Compostos derivados de metil-benzimidazol, processo para a manufatura desses compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ ou profilático de enfermidades que são afetadas por moduladores de fxr e uso de tais compostos
WO2012125007A3 (en) Methods and compositions for the treatment, prevention, and alleviation of bone and cartilage diseases or injuries and hair loss
BRPI0911159A2 (pt) compostos derivados de ácido 4-dimetilaminobutírico, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico ou profilático de enfermidades que são moduladas por inibidres de cpt2 e uso destes compostos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]